|Videos|October 5, 2016

An Overview of Lyme Disease

Richard Krieger, MD, chairman of the Infection Control Committee at Chilton Medical Center, and infectious disease physician at ID care, provides a brief overview of Lyme disease.

Richard Krieger, MD, chairman of the Infection Control Committee at Chilton Medical Center, and infectious disease physician at ID care, provides a brief overview of Lyme disease.

Interview Transcript (slightly modified for readability)

“Lyme disease is something that’s probably been around longer than we realized and it was discovered in Lyme, Connecticut, hence the name, in, believe, the 70’s. They found it was a group of children who were having this unusual arthritis and when they started investigating they found that they had several common factors, like many of them had a particular rash, which we now know is Erythema migrans, and when they investigated they discovered this condition which came to be called Lyme arthritis initially, and then they expanded it to Lyme disease, when they found that it causes other symptoms. It wasn’t until a few years later that they discovered that the organism that caused it was Borrelia burgdorferi and that it can have a lot of different manifestations. Unfortunately there’s a lot of information, but there’s also a lot of misinformation and there’s a lot of abuse in the treatment of Lyme disease out there.”


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
FAQ: What You Need to Know About West Nile Virus in 2026
After 2 adults died of West Nile virus in central North Carolina this month, this FAQ explains how the mosquito-borne virus spreads, who faces the greatest risk of severe neuroinvasive disease, and how clinicians can diagnose, manage, and help prevent infection when no vaccine or antiviral treatment exists.